S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Stock market today: Shares mixed in Asia ahead of updates on jobs, inflation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
All the trading advice you’ve ever received boils down to this (Ad)
Economists predict US inflation will keep cooling and the economy can avoid a recession
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Stock market today: Shares mixed in Asia ahead of updates on jobs, inflation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
All the trading advice you’ve ever received boils down to this (Ad)
Economists predict US inflation will keep cooling and the economy can avoid a recession
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Stock market today: Shares mixed in Asia ahead of updates on jobs, inflation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
All the trading advice you’ve ever received boils down to this (Ad)
Economists predict US inflation will keep cooling and the economy can avoid a recession
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Stock market today: Shares mixed in Asia ahead of updates on jobs, inflation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Alaska Air to buy Hawaiian Airlines in a $1.9 billion deal that may attract regulator scrutiny
Watchdog: Western arms companies failed to ramp up production capacity in 2022 due to Ukraine war
All the trading advice you’ve ever received boils down to this (Ad)
Economists predict US inflation will keep cooling and the economy can avoid a recession
Alaska Air Group announces it has agreed to buy Hawaiian Airlines in a $1.9 billion deal with debt

Amneal Pharmaceuticals Stock Price, News & Analysis (NYSE:AMRX)

$4.66
+0.35 (+8.12%)
(As of 12/1/2023 08:54 PM ET)
Compare
Today's Range
$4.25
$4.69
50-Day Range
$3.36
$4.67
52-Week Range
$1.24
$4.74
Volume
1.51 million shs
Average Volume
1.12 million shs
Market Capitalization
$1.43 billion
P/E Ratio
77.67
Dividend Yield
N/A
Price Target
$4.80

Amneal Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
3.0% Upside
$4.80 Price Target
Short Interest
Bearish
6.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.51
Upright™ Environmental Score
News Sentiment
0.19mentions of Amneal Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.58 out of 5 stars

Medical Sector

871st out of 957 stocks

Pharmaceutical Preparations Industry

407th out of 436 stocks


AMRX stock logo

About Amneal Pharmaceuticals Stock (NYSE:AMRX)

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

AMRX Stock Price History

AMRX Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Amneal Pharmaceuticals Q3 Profit Tops Estimates; Revenue Up 14%
Amneal Reports Third Quarter 2023 Financial Results
Truist Financial Keeps Their Buy Rating on Amneal Pharmaceuticals (AMRX)
Amneal (AMRX) Upgraded to Buy: Here's Why
See More Headlines
Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/03/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/07/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
7,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.80
High Stock Price Target
$7.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+3.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-129,990,000.00
Pretax Margin
1.49%

Debt

Sales & Book Value

Annual Sales
$2.39 billion
Cash Flow
$1.42 per share
Book Value
$0.50 per share

Miscellaneous

Free Float
225,126,000
Market Cap
$1.43 billion
Optionable
Optionable
Beta
1.26
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives















AMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Amneal Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AMRX shares.
View AMRX analyst ratings
or view top-rated stocks.

What is Amneal Pharmaceuticals' stock price target for 2024?

5 Wall Street analysts have issued twelve-month price objectives for Amneal Pharmaceuticals' stock. Their AMRX share price targets range from $3.00 to $7.00. On average, they predict the company's share price to reach $4.80 in the next twelve months. This suggests a possible upside of 3.0% from the stock's current price.
View analysts price targets for AMRX
or view top-rated stocks among Wall Street analysts.

How have AMRX shares performed in 2023?

Amneal Pharmaceuticals' stock was trading at $1.99 on January 1st, 2023. Since then, AMRX stock has increased by 134.2% and is now trading at $4.66.
View the best growth stocks for 2023 here
.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 3,620,000 shares, an increase of 13.5% from the October 31st total of 3,190,000 shares. Based on an average daily volume of 1,230,000 shares, the days-to-cover ratio is currently 2.9 days. Currently, 6.5% of the company's stock are short sold.
View Amneal Pharmaceuticals' Short Interest
.

When is Amneal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our AMRX earnings forecast
.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) released its quarterly earnings data on Tuesday, November, 7th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.07. The company had revenue of $620.04 million for the quarter, compared to analysts' expectations of $613.74 million. Amneal Pharmaceuticals had a net margin of 0.43% and a trailing twelve-month return on equity of 109.82%.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY23 earnings guidance on Monday, October, 23rd. The company provided earnings per share guidance of $0.51-0.58 for the period, compared to the consensus EPS estimate of $0.55. The company issued revenue guidance of $2.37-2.42 billion, compared to the consensus revenue estimate of $2.38 billion.

What is Chirag and Chintu Patel's approval rating as Amneal Pharmaceuticals' CEO?

23 employees have rated Amneal Pharmaceuticals Chief Executive Officer Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among the company's employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Rubric Capital Management LP (1.31%), Rubric Capital Management LP (1.31%), LSV Asset Management (0.47%), Charles Schwab Investment Management Inc. (0.43%), Northern Trust Corp (0.39%) and AQR Capital Management LLC (0.31%). Insiders that own company stock include Andrew S Boyer, Chirag K Patel, Gautam Patel, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:AMRX) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -